Kite Pharma submits MAA for axicabtagene ciloleucel in Europe

US-based cell therapy company Kite Pharma has filed a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for axicabtagene ciloleucel.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news